Rafael Holdings Bets Big on Rare Disease Drug Amid Portfolio Shifts

TL;DR

**RFL is a high-risk bet on a single rare disease drug, Trappsol Cyclo, with other portfolio companies offering limited, speculative upside.**

AI Summary

Rafael Holdings, Inc. (RFL) is a biotechnology company primarily focused on developing Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1), a rare genetic disorder. The company completed a merger with Cyclo Therapeutics, LLC on March 25, 2025, making Cyclo a wholly-owned subsidiary. Trappsol Cyclo is currently in a pivotal Phase 3 clinical trial, having received FDA Fast Track designation in January 2017. RFL also holds majority interests in several other entities: LipoMedix Pharmaceuticals Ltd. (95% ownership), a clinical-stage pharmaceutical company exploring strategic options; Cornerstone Pharmaceuticals, Inc. (67% ownership), a cancer metabolism-based therapeutics company acquired on March 13, 2024, after its lead candidate Devimistat failed Phase 3 trials; Rafael Medical Devices, LLC (73% ownership), which received FDA 510(k) clearance for its VECTR System on December 11, 2024; and Day Three Labs, Inc., which sold assets and licensed its Unlokt technology on March 14, 2025. Barer Institute Inc., a wholly-owned cancer research entity, has substantially curtailed operations. The company's aggregate market value of non-affiliate voting and non-voting stock was approximately $38.6 million as of January 31, 2025.

Why It Matters

Rafael Holdings' strategic pivot to focus on Trappsol Cyclo for NPC1 is a high-stakes move for investors, as the success or failure of this Phase 3 trial will largely dictate the company's future valuation. The FDA's 510(k) clearance for Rafael Medical Devices' VECTR System offers a potential near-term revenue stream, diversifying risk from the long drug development cycle. However, the consolidation of Cornerstone Pharmaceuticals, following its lead drug's Phase 3 failure, highlights the inherent volatility in biotech and the competitive pressures from larger pharmaceutical companies with deeper pipelines and resources. Employees and customers of the acquired entities face uncertainty as RFL evaluates optimal operational directions for these holdings.

Risk Assessment

Risk Level: high — The company explicitly states, "Our future success may depend on the results of the ongoing Phase 3 trial for Trappsol Cyclo." This singular reliance on one drug candidate, coupled with the lengthy and expensive drug development process, presents significant risk. Furthermore, the aggregate market value of non-affiliate voting and non-voting stock was only approximately $38.6 million as of January 31, 2025, indicating a small market capitalization highly susceptible to trial outcomes.

Analyst Insight

Investors should closely monitor the progress and results of the Trappsol Cyclo Phase 3 clinical trial, as this is the primary value driver for RFL. Given the high-risk profile and dependence on a single drug, consider this a speculative investment and allocate capital accordingly, understanding the potential for significant volatility.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• $38.6 million — Aggregate market value of non-affiliate stock (as of January 31, 2025, indicating a small market capitalization)
• 95% — Ownership in LipoMedix Pharmaceuticals Ltd. (reflects a significant majority interest)
• 67% — Ownership in Cornerstone Pharmaceuticals, Inc. (acquired on March 13, 2024, after restructuring)
• 73% — Ownership in Rafael Medical Devices, LLC (after selling 31.6% to third parties)
• 787,163 — Class A common stock shares outstanding (as of October 27, 2025)
• 50,983,641 — Class B common stock shares outstanding (as of October 27, 2025 (excluding treasury shares))
• $2.03 — Class B common stock price per share (on January 31, 2025, used for market value calculation)
• May 2023 — Initial investment in Cyclo (preceding the full merger in March 2025)
• December 11, 2024 — FDA 510(k) clearance for VECTR System (a key regulatory milestone for Rafael Medical Devices)
• March 25, 2025 — Merger with Cyclo consummated (making Cyclo a wholly-owned subsidiary)

Key Players & Entities

• Rafael Holdings, Inc. (company) — registrant
• Trappsol Cyclo (company) — lead drug candidate for NPC1
• Niemann-Pick Disease Type C1 (regulator) — rare genetic disorder
• Cyclo Therapeutics, LLC (company) — wholly-owned subsidiary acquired March 25, 2025
• LipoMedix Pharmaceuticals Ltd. (company) — 95% owned clinical-stage pharmaceutical company
• Cornerstone Pharmaceuticals, Inc. (company) — 67% owned cancer metabolism therapeutics company
• Rafael Medical Devices, LLC (company) — 73% owned orthopedic medical device company
• Day Three Labs, Inc. (company) — majority owned technology company
• FDA (regulator) — granted Fast Track designation and 510(k) clearance
• Howard S. Jonas (person) — Executive Chairman, CEO, President, Chairman of the Board, and controlling stockholder

FAQ

Risk Factors

• Dependence on Trappsol Cyclo Success [high — operational]: The company's primary focus and future prospects are heavily reliant on the successful development and commercialization of Trappsol Cyclo for Niemann-Pick Disease Type C1. Failure in the ongoing pivotal Phase 3 clinical trial or subsequent regulatory approval would severely impact the company's financial condition and ability to continue operations.
• Limited Financial Resources and Need for Funding [high — financial]: As a clinical-stage biotechnology company, RFL requires significant capital for research, development, and clinical trials. The company's aggregate market value of non-affiliate stock was approximately $38.6 million as of January 31, 2025, suggesting a small market capitalization. This may necessitate future equity or debt financing, which may not be available on favorable terms or at all.
• Regulatory Approval Risks [high — regulatory]: The development of pharmaceutical products like Trappsol Cyclo is subject to stringent regulatory review by agencies such as the FDA. The Fast Track designation for Trappsol Cyclo in January 2017 is a positive step, but it does not guarantee approval. Delays or failure to obtain regulatory approval for Trappsol Cyclo or other product candidates would significantly hinder the company's business objectives.
• Competition in Rare Disease Market [medium — market]: While NPC1 is a rare disease, the company faces competition from other entities developing treatments for rare genetic disorders. The success of competitors' therapies could impact market share and pricing for Trappsol Cyclo if approved. The company also holds interests in other companies, each facing their own competitive landscapes.
• Reliance on Majority-Owned Subsidiaries [medium — operational]: Rafael Holdings derives a significant portion of its potential value and future opportunities from its majority-owned subsidiaries, including LipoMedix Pharmaceuticals Ltd., Cornerstone Pharmaceuticals, Inc., and Rafael Medical Devices, LLC. The performance and strategic success of these entities directly impact the overall financial health and strategic direction of Rafael Holdings.
• Uncertainty of Investments in Other Companies [medium — financial]: The company holds majority interests in several entities with varying stages of development and success. Cornerstone Pharmaceuticals' lead candidate failed Phase 3 trials, and Day Three Labs sold assets. The future value and strategic contribution of these investments are uncertain and subject to market conditions and further development outcomes.
• Curtailed Operations of Barer Institute [low — operational]: The substantial curtailment of operations at Barer Institute Inc., a wholly-owned cancer research entity, indicates a strategic shift or resource reallocation, potentially impacting the company's diversified research capabilities and future pipeline diversification.

Industry Context

Rafael Holdings operates within the biotechnology and pharmaceutical sector, with a specific focus on rare diseases and oncology. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies often pursue strategic partnerships, acquisitions, and divestitures to manage risk and capital. The rare disease market, while niche, offers potential for premium pricing and expedited regulatory pathways, as seen with the Fast Track designation for Trappsol Cyclo.

Regulatory Implications

The company's primary drug candidate, Trappsol Cyclo, is subject to rigorous FDA review. The Fast Track designation is a positive indicator, but the success of the pivotal Phase 3 trial and subsequent approval are not guaranteed. Delays or rejections pose significant risks. Additionally, the medical device subsidiary, Rafael Medical Devices, has achieved 510(k) clearance for its VECTR System, indicating a successful navigation of a specific regulatory pathway for devices.

What Investors Should Do

1. Monitor Phase 3 Trial Results for Trappsol Cyclo
2. Assess Funding Needs and Capital Structure
3. Evaluate Performance of Majority-Owned Subsidiaries
4. Track Regulatory Developments

Key Dates

• 2017-01-01: FDA Fast Track Designation for Trappsol Cyclo — Indicates potential for expedited review and development for NPC1 treatment, a critical step for a rare disease drug.
• 2023-05-01: Initial Investment in Cyclo Therapeutics — Marked the beginning of the company's strategic focus on Trappsol Cyclo and its development for neurodegenerative diseases.
• 2024-03-13: Acquisition of Cornerstone Pharmaceuticals, Inc. — Expanded the company's portfolio into cancer metabolism therapeutics, though the lead candidate later failed Phase 3.
• 2024-12-11: FDA 510(k) Clearance for VECTR System — A significant regulatory milestone for Rafael Medical Devices, LLC, validating its orthopedic medical device technology.
• 2025-03-14: Day Three Labs, Inc. Asset Sale and Licensing — Indicates a strategic divestment or restructuring for Day Three Labs, impacting its contribution to Rafael Holdings.
• 2025-03-25: Merger with Cyclo Therapeutics, LLC Consummated — Made Cyclo Therapeutics a wholly-owned subsidiary, consolidating the development of Trappsol Cyclo under Rafael Holdings.

Glossary

Trappsol Cyclo

A cyclodextrin-based product candidate being developed for the treatment of Niemann-Pick Disease Type C1. (It is the company's lead drug candidate and the primary focus of its development efforts.)

Niemann-Pick Disease Type C1 (NPC1)

A rare, fatal, and progressive genetic disorder characterized by disrupted cholesterol metabolism, affecting multiple organs. (The specific rare disease for which Trappsol Cyclo is being developed.)

FDA Fast Track Designation

A process by which the FDA expedites the development and review of drugs intended to treat serious conditions and fill unmet medical needs. (Indicates that Trappsol Cyclo has met certain criteria for accelerated development and potential approval.)

Pivotal Phase 3 Clinical Trial

The final stage of clinical testing in humans, designed to confirm the efficacy and safety of a drug in a large patient population. (The success of this trial is critical for the potential regulatory approval and commercialization of Trappsol Cyclo.)

Cyclodextrin

A group of cyclic oligosaccharides derived from starch, used in various applications including drug delivery. (The chemical basis of the Trappsol Cyclo drug candidate.)

Cancer Metabolism-Based Therapeutics

Therapies that target the altered metabolic pathways that cancer cells rely on for growth and survival. (The focus of Cornerstone Pharmaceuticals, Inc., one of Rafael Holdings' majority-owned subsidiaries.)

FDA 510(k) Clearance

A premarket notification process by which the FDA determines if a medical device is substantially equivalent to a legally marketed device. (Represents regulatory approval for the VECTR System developed by Rafael Medical Devices, LLC.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text. The filing focuses on the current period's business overview, risk factors, and key dates, without explicit year-over-year financial comparisons or narrative on changes in risks.

Key Financial Figures

• $0.01 — stered Class B common stock, par value $0.01 per share RFL New York Stock Exchange
• $2.03 — quarter) of the Class B common stock of $2.03 per share, as reported on the New York
• $925,000 — 6% equity interest to third parties for $925,000. In February 2025, we invested approxim
• $582,000 — ebruary 2025, we invested approximately $582,000 in cash, and Rafael Medical Devices rai
• $44,000 — el Medical Devices raised approximately $44,000 from third parties in exchange for Rafa

Filing Documents

• ea0262395-10k_rafael.htm (10-K) — 2426KB
• ea026239501ex4-2_rafael.htm (EX-4.2) — 20KB
• ea026239501ex19-01_rafael.htm (EX-19.01) — 82KB
• ea026239501ex21-01_rafael.htm (EX-21.01) — 3KB
• ea026239501ex23-1_rafael.htm (EX-23.1) — 2KB
• ea026239501ex31-01_rafael.htm (EX-31.1) — 9KB
• ea026239501ex31-02_rafael.htm (EX-31.2) — 8KB
• ea026239501ex32-01_rafael.htm (EX-32.1) — 4KB
• ea026239501ex32-02_rafael.htm (EX-32.2) — 4KB
• ea026239501ex97_rafael.htm (EX-97) — 15KB
• ex97_001.jpg (GRAPHIC) — 9KB
• 0001213900-25-103549.txt ( ) — 13719KB
• rfl-20250731.xsd (EX-101.SCH) — 139KB
• rfl-20250731_cal.xml (EX-101.CAL) — 125KB
• rfl-20250731_def.xml (EX-101.DEF) — 705KB
• rfl-20250731_lab.xml (EX-101.LAB) — 1224KB
• rfl-20250731_pre.xml (EX-101.PRE) — 722KB
• ea0262395-10k_rafael_htm.xml (XML) — 1461KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 29 Item 1B. Unresolved Staff Comments 80 Item 1C. Cybersecurity 80 Item 2.

Properties

Properties 80 Item 3.

Legal Proceedings

Legal Proceedings 80 Item 4. Mine Safety Disclosures 80 Part II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 81 Item 6. [Reserved] 81 Item 7A. Quantitative and Qualitative Disclosures about Market Risks 90 Item 7.

Management's Discussion and Analysis of

Management's Discussion and Analysis of Financial Condition and Results of Operations 82 Item 8.

Financial Statements and Supplementary

Financial Statements and Supplementary Data 90 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 90 Item 9A.

Controls and Procedures

Controls and Procedures 90 Item 9B. Other Information 91 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 91 Part III Item 10. Directors, Executive Officers and Corporate Governance 92 Item 11.

Executive Compensation

Executive Compensation 92 Item 12.

Security Ownership of Certain Beneficial

Security Ownership of Certain Beneficial 92 Item 13. Certain Relationships and Related Transactions, and Director Independence 92 Item 14. Principal Accounting Fees and Services 92 Part IV Item 15. Exhibits, Financial Statement Schedules 93 Item 16. Form 10-K Summary 94

SIGNATURES

SIGNATURES 95 i This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that contain the words "believes," "anticipates," "expects," "plans," "intends" and similar words and phrases. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the results projected in any forward-looking statement. In addition to the factors specifically noted in the forward-looking statements, other important factors, risks and uncertainties that could result in those differences include, but are not limited to, those discussed under Item 1A to Part I "Risk Factors" in this Annual Report. The forward-looking statements are made as of the date of this Annual Report, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth in this report and the other information set forth from time to time in our reports filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933 and the Securities Exchange Act of 1934, including our reports on Forms 10-Q and 8-K. Our business, operating results or financial condition could be materially adversely affected by any of the following risks associated with any one of our businesses, as well as the other risks highlighted elsewhere in this document. The trading price of our common stock could decline due to any of these risks. Note that references to "our", "us", "we", "the Company", etc. used in each risk factor below refers to the business about which such risk factor is provided. Our business is subject to numerous risks as described in Item 1A. Risk Factors. Some of these risks include: We have limited resources and could find it

Business

Item 1. Business. OVERVIEW Rafael Holdings, Inc. ("Rafael Holdings", "Rafael", "we" or the "Company") is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder. We also hold: (i) a majority equity interest in LipoMedix Pharmaceuticals Ltd. ("LipoMedix"), a clinical stage pharmaceutical company; (ii) Barer Institute Inc. ("Barer"), a wholly-owned cancer research focused entity whose operations have been substantially curtailed; (iii) a majority interest in Cornerstone Pharmaceuticals, Inc. ("Cornerstone"), formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company; (iv) a majority interest in Rafael Medical Devices, LLC ("Rafael Medical Devices"), an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries; and (v) a majority interest in Day Three Labs, Inc. ("Day Three"), a company which empowers third-party manufacturers to reimagine their existing product offerings by utilizing Day Three's technology and innovation like Unlokt. Our primary focus has been the continued development of Trappsol Cyclo through the completion of its ongoing pivotal Phase 3 clinical trial, the potential filing for regulatory approval and ultimately, if approved, commercialization of the product. We also look to expand our investment portfolio through opportunistic and strategic investments including that address high unmet medical needs. We continuously evaluate our other holdings to ensure the focus of our resources are on core assets and specifically the continued development of Trappsol Cyclo . Historically, we owned real estate assets. As of July 31, 2025, we hold a portion of a commercial buildin

View Full Filing

View this 10-K filing on SEC EDGAR